Compare GSK plc (GSK) vs Kimberly Clark Corp (KMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Kimberly Clark Corp — how do they compare? GSK plc trades at $52.56 (market cap $101.34B), while Kimberly Clark Corp trades at $108.48 (market cap $35.36B). The key difference: GSK plc is far larger — about 2.9× Kimberly Clark Corp's market cap, and Kimberly Clark Corp pays the higher dividend (4.81%). Which is the better fit depends on your goals.
| GSK | KMB | |
|---|---|---|
Market Cap | $101.34B | $35.36B |
Sector | Health | Consumer Staples |
52-Week High | $61.18 | $136.77 |
52-Week Low | $36.20 | $93.05 |
Enterprise Value | $121.95B | $41.90B |
Dividend Yield | 3.49% | 4.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Kimberly-Clark (KMB) trades at $106.82, down 3.05% on the day, near the analyst low target of $106.00. The stock shows a bullish technical signal with RSI at 24.78 indicating potential oversold conditions, while recent quarterly EPS beats and a 4.5% dividend yield highlight fundamental strength. The company's pending Kenvue acquisition and innovation-driven growth strategy are key developments, though revenue declined to $16.45B in 2025 from $20.1B in 2024.
KMB offers a stable income play with consistent dividend payments, but investors face risks from high payout ratios and competitive pressures. Analyst consensus is mixed with 32% buy ratings, suggesting cautious optimism. Near-term performance hinges on Q2 2026 earnings due August 4, 2026, with margins under scrutiny amid input cost inflation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →
